Lung Cancer
A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + PlatinumChemotherapy with or without Pembrolizumab (MK-3475) in TKI-resistant EGFR-mutated Tumors in Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) Participants (KEYNOTE-789; MK-3475-789)
- Details
ClinicalTrials.gov ID:
NCT03515837
Diagnosis Type:
NA
USOR Number:
- Address
8196 Walnut Hill Lane, Suite 100
Dallas, TX 75231
P: (214) 345-7394